Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
We know rare cannabinoids in depth
InMed is a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids.
Learn More

Unparalleled rare cannabinoid expertise

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

Learn More

Unlocking the therapeutic potential of rare cannabinoids

Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.

Learn about our rare cannabinoid programs
BayMedica logo square

Bringing you highly pure, premium bioidentical rare cannabinoids

InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. We have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. We currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBTC) which are available for B2B purchase.

Learn about our BAYMEDICA'S PRODUCTS

A library of cannabinoid analogs that can be selectively modified

Unlike natural cannabinoids isolated from the plant which are not patentable, our proprietary cannabinoid analogs are patentable and are recognized as new chemical entities (NCEs). These analogs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases. We are screening these analogs for their therapeutic properties and pharmaceutical development.

Learn About Our Cannabinoid Analogs

Experienced team with a successful track record

Together, InMed and BayMedica bring extensive know-how in cannabinoid science, manufacturing and development. We’ve combined our complementary expertise to become a leading manufacturer and developer of high-quality rare cannabinoids.

Meet the team

Latest News

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023
Read More »

InMed to Participate in Upcoming Investor Events

March 6, 2023
Read More »

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023
Read More »

InMed Submits Form 12b-25

February 9, 2023
Read More »

InMed Provides Business Update and Milestones for 2023

January 10, 2023
Read More »

InMed Announces Results of 2022 Annual General Meeting

December 15, 2022
Read More »

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023
Learn More

InMed to Participate in Upcoming Investor Events

March 6, 2023
Learn More

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023
Learn More

InMed Submits Form 12b-25

February 9, 2023
Learn More

InMed Provides Business Update and Milestones for 2023

January 10, 2023
Learn More

InMed Announces Results of 2022 Annual General Meeting

December 15, 2022
Learn More
See all news

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP


INM-755

A cannabinol (CBN) topical cream in Phase 2 clinical trials for epidermolysis bullosa
Learn More

THCV Tetrahydrocanabivarin

InMed's subsidiary BayMedica has begun B2B sales of d9-THCV for the health and wellness industry
Learn More

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent